Equities analysts expect that Sage Therapeutics, Inc. (NASDAQ:SAGE – Get Rating) will post earnings of ($2.03) per share for the current quarter, Zacks reports. Twelve analysts have made estimates for Sage Therapeutics’ earnings, with estimates ranging from ($2.51) to ($0.78). Sage Therapeutics posted earnings per share of ($1.83) in the same quarter last year, which indicates a negative year-over-year growth rate of 10.9%. The firm is expected to announce its next earnings report on Monday, January 1st.
According to Zacks, analysts expect that Sage Therapeutics will report full year earnings of ($8.66) per share for the current fiscal year, with EPS estimates ranging from ($10.17) to ($7.55). For the next fiscal year, analysts forecast that the firm will post earnings of ($7.33) per share, with EPS estimates ranging from ($9.97) to ($4.09). Zacks’ EPS calculations are a mean average based on a survey of research analysts that follow Sage Therapeutics.
Sage Therapeutics (NASDAQ:SAGE – Get Rating) last issued its quarterly earnings data on Tuesday, May 3rd. The biopharmaceutical company reported ($2.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.06) by ($0.01). Sage Therapeutics had a negative return on equity of 27.23% and a negative net margin of 7,676.91%. The company had revenue of $1.58 million for the quarter, compared to the consensus estimate of $3.23 million. During the same period in the prior year, the company earned ($1.64) EPS. The firm’s revenue was down .1% on a year-over-year basis.
In related news, Director George Golumbeski bought 8,000 shares of the business’s stock in a transaction dated Thursday, May 5th. The stock was bought at an average price of $31.45 per share, for a total transaction of $251,600.00. Following the purchase, the director now owns 8,000 shares in the company, valued at approximately $251,600. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 4.70% of the company’s stock.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. US Bancorp DE raised its stake in Sage Therapeutics by 19.7% in the 3rd quarter. US Bancorp DE now owns 1,885 shares of the biopharmaceutical company’s stock worth $84,000 after purchasing an additional 310 shares in the last quarter. Fiduciary Trust Co. raised its stake in Sage Therapeutics by 1.4% in the 3rd quarter. Fiduciary Trust Co. now owns 26,000 shares of the biopharmaceutical company’s stock worth $1,152,000 after purchasing an additional 350 shares in the last quarter. DekaBank Deutsche Girozentrale raised its stake in Sage Therapeutics by 2.1% in the 1st quarter. DekaBank Deutsche Girozentrale now owns 22,220 shares of the biopharmaceutical company’s stock worth $762,000 after purchasing an additional 450 shares in the last quarter. Pinnacle Associates Ltd. raised its stake in Sage Therapeutics by 0.4% in the 4th quarter. Pinnacle Associates Ltd. now owns 178,892 shares of the biopharmaceutical company’s stock worth $7,610,000 after purchasing an additional 651 shares in the last quarter. Finally, Teacher Retirement System of Texas raised its stake in Sage Therapeutics by 6.8% in the 1st quarter. Teacher Retirement System of Texas now owns 10,927 shares of the biopharmaceutical company’s stock worth $362,000 after purchasing an additional 698 shares in the last quarter. Institutional investors own 84.40% of the company’s stock.
Shares of SAGE stock opened at $32.24 on Friday. The firm has a fifty day moving average of $33.25 and a 200-day moving average of $37.09. Sage Therapeutics has a 12-month low of $27.36 and a 12-month high of $79.45. The company has a market capitalization of $1.90 billion, a price-to-earnings ratio of -3.92 and a beta of 1.57.
About Sage Therapeutics (Get Rating)
Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, treatment resistant disorders, generalized anxiety disorders, and bipolar depression; and SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases.
- Get a free copy of the StockNews.com research report on Sage Therapeutics (SAGE)
- These Are the Three (3) Most Upgraded Stocks For Q2
- MarketBeat: Week in Review 5/23 – 5/27
- Short Sellers Provide Entry Into Hibbet, Inc At Rock Bottom Prices
- Affirm Stock Has Affirmed a Bottom
- Airbnb: Bold Competitive Threats & A New World of Travel
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sage Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sage Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.